Pfizer pricing
Executive Summary
1992 weighted average price increase for total product line will be "a little under 2%," company CEO William Steere tells April 23 annual shareholders' meeting. Pfizer received several new product approvals in 1991 and early 1992, which might account in part for the modest price increases. Steere also informed investors that Pfizer's Pratt Pharmaceuticals subsidiary had received 65,000 applications for 500 new sales positions.